Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Kinaset Therapeutics $103M Series BParabilis Medicines $305M Series FRanked by rounds participated in, from announcements in Jan 1, 2026 – Jan 31, 2026. Lead counts include only confirmed lead roles.
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Kinaset Therapeutics $103M Series BParabilis Medicines $305M Series FNew companies 2 · Follow-on 0
Stages: Series B 2
Kinaset Therapeutics $103M Series BEpiBiologics $107M Series BNew companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
Hadrian Undisclosed UndisclosedValinor Enterprises $54M Series ANew companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
AirNexis Therapeutics $200M Series AParabilis Medicines $305M Series FNew companies 2 · Follow-on 0
Stages: Series A 2
Ventaris Surgical $30M Series AAirNexis Therapeutics $200M Series ANew companies 2 · Follow-on 0
Stages: Series A 2
AirNexis Therapeutics $200M Series APoplar Therapeutics $50M Series ANew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Luxury Presence $37M Series CCambium $100M Series BNew companies 2 · Follow-on 0
Stages: Series A 1, Undisclosed 1
United Manufacturing Hub €5M UndisclosedArray Labs $20M Series ANew companies 2 · Follow-on 0
Stages: Seed 1, Series B 1
Enodia Therapeutics €20.7M SeedEpiBiologics $107M Series BNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
EpiBiologics $107M Series BParabilis Medicines $305M Series FNew companies 2 · Follow-on 0
Stages: Pre-seed 1, Undisclosed 1
Biographica £7M UndisclosedWholeSum £730K Pre-Seed“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.